Recruiting PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT06384807

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

A Phase 1/2, First in Human, Dose Escalation and Dose Expansion Study of BHV-1510 (Previously PBI-410) as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumors

Sponsor: Biohaven Therapeutics Ltd.

Conditions Solid Tumor

Interventions BHV-1510 Cemiplimab

Updated 11 times since 2024 Last updated: Mar 9, 2026 Started: Apr 22, 2024 Primary completion: Feb 29, 2028 Completion: Feb 29, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Solid Tumor and is currently actively recruiting participants. Biohaven Therapeutics Ltd. leads this study, which shows 11 recorded versions since 2024 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

11 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE1/PHASE2
Dec 2025 — Mar 2026 [monthly]

Recruiting PHASE1/PHASE2
Sep 2025 — Dec 2025 [monthly]

Recruiting PHASE1/PHASE2
Jul 2025 — Sep 2025 [monthly]

Recruiting PHASE1/PHASE2
Jun 2025 — Jul 2025 [monthly]

Recruiting PHASE1/PHASE2

▶ Show 6 earlier versions

Feb 2025 — Jun 2025 [monthly]

Recruiting PHASE1/PHASE2
Dec 2024 — Feb 2025 [monthly]

Recruiting PHASE1/PHASE2
Nov 2024 — Dec 2024 [monthly]

Recruiting PHASE1/PHASE2
Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Status: Not Yet Recruiting → Recruiting · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
May 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Apr 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biohaven Therapeutics Ltd.

Data source: Biohaven Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Augusta, United States , Dallas, United States , Detroit, United States , Duarte, United States , Fairfax, United States , La Jolla, United States , Miami, United States , Nashville, United States , New York, United States , Oklahoma City, United States and 7 more locations